Freeman Chris

Freeman Chris, Chief Commercial Officer at Guardant Health (GH), has filed 61 Form 4 transactions, all in the single company. The pattern is one-sided: zero open-market purchases and roughly $16.9 million in total sales, with no acquisitions outside of option exercises and stock awards. The most recent cluster, filed October 1, 2026, consists of four option exercises valued at zero and a tax-withholding disposition of $549,239. That follows a larger August 10, 2026 batch of three open-market sales totaling $10.2 million, alongside two option exercises worth $4.7 million combined. The selling has been steady through the year. On May 22, 2026, Freeman sold $2.9 million in GH stock and exercised options valued at $802,000. A July 1 filing showed four zero-value option exercises and a $536,389 tax withholding. Smaller tax-related dispositions appeared on June 15 ($77,113) and April 1 ($432,963). The August sales dominate the dollar volume: $5,998,926, $2,964,401, $1,243,145, and $579,639, all on the same day. The Form 4 codes clarify the mechanics. The "M" entries are option exercises, which are mechanical and add no cash to the seller's pocket at exercise. The "F" entries are shares withheld to cover tax obligations, automatic and not discretionary. The "S" codes are the only true open-market sales, and they account for nearly all of the $16.9 million total. Freeman has not bought a single share on the open market across the entire filing history, so the bias is consistently toward reducing exposure, with the largest disposals concentrated in August 2026.